[1] World Health Organization (1972) International Drug Monitoring: The Role of National Centers. Technical Report Series No. 498, World Health Organization, Geneva.
[2] Kalaiselvan, V., Mishra, P. and Singh, G.N. (2014) Helpline Facility to Assist Reporting of Adverse Drug Reactions in India. WHO South East Asia Journal of Public Health, 3, 194.
[3] Ishiguro, C., Hall, M., Neyarapally, G.A. and Dal Pan, G. (2012) Post-Market Drug Safety Evidence Sources: An Analysis of FDA Drug Safety Communications. Pharmacoepidemiology and Drug Safety, 21, 1134-1136.
http://dx.doi.org/10.1002/pds.3317
[4] Watson, R. (2012) New EU Drug Safety Committee Ends National Reporting of Drug Reactions. BMJ, 345, e4690.
http://dx.doi.org/10.1136/bmj.e4690
[5] Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Farrar, K., Park, B.K. and Breckenridge, A.M. (2004) Adverse Drug Reactions as Cause of Admission to Hospital: Prospective Analysis of 18,820 Patients. BMJ, 329, 15-19.
http://dx.doi.org/10.1136/bmj.329.7456.15
[6] Sarker, A., Ginn, R., Nikfarjam, A., O’Connor, K., Smith, K., Jayaraman, S., et al. (2015) Utilizing Social Media Data for Pharmacovigilance: A Review. Journal of Biomedical Informatics, 54, 202-212.
http://dx.doi.org/10.1016/j.jbi.2015.02.004
[7] Harmark, L., van Hunsel, F. and Grundmark, B. (2015) ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems. Drug Safety, 38, 337-347.
http://dx.doi.org/10.1007/s40264-015-0264-1
[8] Robertson, J. and Newby, D.A. (2013) Low Awareness of Adverse Drug Reaction Reporting Systems: A Consumer Survey. MJA, 199, 684-686.
http://dx.doi.org/10.5694/mja13.10069
[9] Passier, A., ten Napel, M., van Grootheest, K. and van Puijenbroek, E. (2009) Reporting of Adverse Drug Reactions by General Practitioners. A Questionnaire-Based Study in the Netherlands. Drug Safety, 32, 851-858.
http://dx.doi.org/10.2165/11314490-000000000-00000
[10] World Health Organization (2002) The Importance of Pharmacovigilance: An Essential Tool. WHO, Geneva.
[11] World Health Organization (2002) Safety of Medicines—A Guide to Detecting and Reporting of Adverse Drug Reactions. Why Health Professionals Need to Take Action. WHO, Geneva.
[12] Hughes, L., Whittlesea, C. and Luscombe, D. (2002) Patients’ Knowledge and Perceptions of the Side-Effects of OTC Medication. Journal of Clinical Pharmacy and Therapeutics, 27, 243-248.
http://dx.doi.org/10.1046/j.1365-2710.2002.00416.x
[13] Jha, N., Ratthore, D.S., Shankar, P.R. and Gyawali, S. (2014) Pharmacovigilance Knowledge among Patients at a Teaching Hospital in Lalitpur District, Nepal. Journal of Clinical and Diagnostic Research, 8, 32-34.
http://dx.doi.org/10.7860/jcdr/2014/7378.4097
[14] Elkalmi, R., Hassali, M.A., Al-Lela, O.Q., Jawad Awadh, A.I., Al-Shami, A.K. and Jamshed, S.Q. (2013) Adverse Drug Reactions Reporting: Knowledge and Opinion of General Public in Penang, Malaysia. Journal of Pharmacy and Bioallied Sciences, 5, 224-228.
http://dx.doi.org/10.4103/0975-7406.116824
[15] Blenkinsopp, A., Wilkie, P., Wang, M. and Routledge, P.A. (2006) Patient Reporting of Suspected Adverse Drug Reactions: A Review of Published Literature and International Experience. British Journal of Clinical Pharmacology, 63, 148-156.
http://dx.doi.org/10.1111/j.1365-2125.2006.02746.x
[16] Hartigan-Go, K. (2002) Developing a Pharmacovigilance System in the Philippines, a Country of Diverse Culture and Strong Traditional Medicine Background. Toxicology, 181-182, 103-107.
http://dx.doi.org/10.1016/S0300-483X(02)00263-9
[17] Vessal, G., Mardani, Z. and Mollai, M. (2009) Knowledge, Attitudes, and Perceptions of Pharmacists to Adverse Drug Reaction Reporting in Iran. Pharmacy World & Science, 31, 183-187.
http://dx.doi.org/10.1007/s11096-008-9276-6
[18] Ahmed, A.M., Izham, I.M. and Subish, P. (2010) Importance of Consumer Pharmacovigilance System in Developing Countries: A Case of Malaysia. Journal of Clinical and Diagnostic Research, 4, 2929-2935.
[19] Palaian, S., Alshakka, M. and Izham, M. (2010) Developing a Consumer Reporting Program in Malaysia: A Novel Initiative to Improve Pharmacovigilance. Pharmacy World & Science, 32, 2-6.
http://dx.doi.org/10.1007/s11096-009-9342-8
[20] World Health Organization (2012) Safety Monitoring of Medicinal Products: Reporting System for the General Public.
http://www.who.int/medicines/areas/quality_safety/safety_efficacy/qas_
safetymonitoringmp/en/
[21] Avery, A.J., Anderson, C., Bond, C.M., Fortnum, H., Gifford, A., Hannaford, P.C., et al. (2011) Evaluation of Patient Reporting of Adverse Drug Reactions to the UK “Yellow Card Scheme”: Literature Review, Descriptive and Qualitative Analyses, and Questionnaire Surveys. Health Technology Assessment, 15, 1-4.
http://dx.doi.org/10.3310/hta15200
[22] Harmark, L., van Hunsel, F. and Grundmark, B. (2015) ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems. Drug Safety, 38, 337-347.
http://dx.doi.org/10.1007/s40264-015-0264-1
[23] Margraff, F. and Bertram, D. (2014) Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries. Drug Safety, 37, 409-419.
http://dx.doi.org/10.1007/s40264-014-0162-y
[24] World Health Organization (2006) The Safety of Medicines in Public Health Programs: Pharmacovigilance an Essential Tool. WHO, Geneva.